Hydronephrosis

Clarius Adds AI-Driven Automatic Bladder Volume Measurements to its Wireless Handheld Ultrasound Scanners Designed for Acute Care, Urology, and Nursing

Retrieved on: 
Tuesday, January 9, 2024
Clarius, Patient, Catheter, Cauda equina syndrome, Literature, Urine, Rehabilitation, Education minister, Abdominal pain, Ultrasound, Urinary retention, Nursing, Food, Nursing home, UI, FDA, Hydronephrosis, PMID, Diagnosis, Urinary tract obstruction, Physician

VANCOUVER, BC, Jan. 9, 2024 /PRNewswire/ -- Clarius Mobile Health, a global leader in wireless ultrasound solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Clarius Bladder AI, a non-invasive tool that automatically measures bladder volume in seconds. It's available now in the United States with the Clarius PAL HD3, Clarius PA HD3 and the Clarius C3 HD3 wireless handheld ultrasound scanners.

Key Points: 
  • It's available now in the United States with the Clarius PAL HD3 , Clarius PA HD3 and the Clarius C3 HD3 wireless handheld ultrasound scanners.
  • The latest addition to the Clarius AI portfolio , Clarius Bladder AI accurately measures bladder volume and provides real-time feedback to clinicians.
  • Clarius Bladder AI is included among other advanced software features that are available with the Advanced Primary / Critical Care Package , included with Clarius Membership .
  • Current Clarius members with eligible scanners will be able to use the new application on their Clarius scanners today.

The Global Nephrostomy Devices market is Expected to Increase by 8% During the Forecast Period, 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Medical devices, Health, Medical specialties, RTT, Medicine, Clinical medicine, Infectious causes of cancer, Urinary system, Kidney diseases, Nephrostomy, Nephrology, Hydronephrosis, Prostate cancer, Ureter

The "Nephrostomy Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nephrostomy Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • According to this research, the Global Nephrostomy Devices Market is expected to grow at a CAGR of 8.0% during the forecast period.
  • Factors such as growing incidence of kidney stone and rising incidence of ovarian cancer, bladder cancer and prostate cancer are propelling the market growth.
  • Hydronephrosis is the common indication characterized by blockade of one or both the ureters, for which nephrostomy catheters are used.

Global Hydronephrosis Therapies Market 2019-2023 with Allergan, F. Hoffmann-La Roche, Novartis, Pfizer & Teva Pharmaceutical Industries Dominating

Retrieved on: 
Wednesday, November 21, 2018
Neurochemistry, Cell signaling, Medicine, Hydronephrosis, Nephrology, Kidney, Ketamine

The "Global Hydronephrosis Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hydronephrosis Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.
  • The report covers the present scenario and the growth prospects of the hydronephrosis therapies market.
  • According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market.